Trial Profile
S-Equol in Alzheimer's Disease 2 (SEAD2) Trial
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs AUS 131 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms SEAD2
- 11 Aug 2021 Status changed from recruiting to completed.
- 26 Apr 2021 Planned End Date changed from 30 Nov 2020 to 30 Sep 2021.
- 26 Apr 2021 Planned primary completion date changed from 30 Sep 2020 to 30 Sep 2021.